This page shows the latest CAR-T cell therapy news and features for those working in and with pharma, biotech and healthcare.
The screening tool enables large-scale testing of the latest immunotherapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, a treatment effective against many haematological cancers but one that presents ... CAR-T cell development is expensive
The data shows the potential of Kymriah as a cure, and as the only CAR T-cell therapy available for such patients who have previously had limited treatment options. ... The ELIANA trial was the first worldwide CAR T-cell therapy registration study,
Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma. ... Novartis has announced that the European Commission (EC) has approved its CAR-T cell therapy, Kymriah (tisagenlecleucel), for the treatment of adult
The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers. ... CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment.
After forming a partnership to develop a multiple myeloma CAR-T cell therapy, Bristol Myers Squibb (BMS) and 2seventy bio have announced that the development plans have been scrapped, while sales ... oncology cell therapy, our vision is simple: design,
Its portfolio includes a development and commercialisation deal with Bristol Myers Squibb for Abecma (idecabtagene vicleucel), its B-cell maturation antigen (BCMA)-directed CAR T-cell therapy approved by the Food ... The next six months looks set to be
More from news
Approximately 4 fully matching, plus 51 partially matching documents found.
EBCs also demonstrate positive data and are bringing novel therapies to market in complex areas of medicine, including gene therapy, CAR T-cell therapy and rare diseases. ... These visuals got the message across in an engaging, novel and efficient manner
Chimeric antigen receptor T-cell therapy. Chimeric antigen receptor (CAR) T-cell therapy consists of engineering receptors in the body that selectively interact with cancer cells, inducing cell death without affecting ... CAR-T therapy has potential
In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... We estimate the cost [of making a CAR-T cell therapy for a single
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The analysts predict the drug will be priced at around $550,
Cell therapy products based on antigen presenting cells. for target‐specific killer CD8 T‐cell responses. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.
More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.
He is part of a team using a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy, which is transforming outcomes for children who would otherwise have no treatment options left. ... SA: CAR-T cell therapy is an innovative immunotherapy that
The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when
Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US. ... The approach is to deliver treatments which restore or establish normal cell
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...